Captor Therapeutics Spolka Akcyjna

Warsaw Stock Exchange CTX.WA

Captor Therapeutics Spolka Akcyjna Capital Expenditure for the year ending December 31, 2023: USD -762.04 K

Captor Therapeutics Spolka Akcyjna Capital Expenditure is USD -762.04 K for the year ending December 31, 2023, a -274.30% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Captor Therapeutics Spolka Akcyjna Capital Expenditure for the year ending December 31, 2022 was USD -203.59 K, a 83.90% change year over year.
Captor Therapeutics Spolka Akcyjna Capital Expenditure for the year ending December 31, 2021 was USD -1.26 M, a -2,128.47% change year over year.
Captor Therapeutics Spolka Akcyjna Capital Expenditure for the year ending December 31, 2020 was USD -56.76 K, a 5.81% change year over year.
Captor Therapeutics Spolka Akcyjna Capital Expenditure for the year ending December 31, 2019 was USD -60.26 K, a -125.73% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Warsaw Stock Exchange: CTX.WA

Captor Therapeutics Spolka Akcyjna

CEO	Dr. Thomas Shepherd Ph.D.
IPO Date	April 1, 2021
Location	Poland
Headquarters	ul. Dunska 11
Employees	105
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.

Key trends

Past 5 years